test_type,sample_number,clinical_text,is_realistic,case_id
WES,1,"Sample Patient: At 17 weeks’ gestation, this pregnancy is being evaluated for suspected Hirschsprung disease, with concern present since early gestation; the family was referred by their primary care physician, and prenatal whole-exome sequencing (WES) is being pursued. Prior Fragile X testing was non-diagnostic. Family history is notable for a maternal aunt with a known pathogenic BRCA1/2 variant. Coverage is through UnitedHealthcare Choice Plus.",True,WES_1
WES,2,"Sample Patient: A 68-year-old woman with gynecologic symptoms dating back to her early 40s—initially irregular heavy bleeding that progressed to postmenopausal bleeding with intermittent pelvic pain and imaging showing endometrial thickening with a complex adnexal cyst—was referred by her gynecologist for genetic evaluation of a substantial single–organ system abnormality and possible hereditary cancer risk; prior fluorescence in situ hybridization (FISH) testing was non-diagnostic. Family history is notable for a father with metastatic prostate cancer. She is insured through the Blue Cross Blue Shield Service Benefit Plan (Federal Employee Program), and whole exome sequencing is being pursued.",True,WES_2
WES,3,"Sample Patient: A 73-year-old patient presents for genetic evaluation of a lifelong complex neurodevelopmental disorder, first recognized in early childhood as global developmental delays with persistent cognitive and adaptive functioning challenges, accompanied by additional abnormalities involving at least one other organ system; they were referred by a neonatologist for consideration of hereditary etiologies. Family history is notable for a brother with global developmental delay. Whole exome sequencing is being pursued to investigate an underlying genetic cause. The patient declined pre-test genetic counseling and has also declined planned post-test counseling. Insurance coverage is through Cigna True Choice Medicare (PPO).",False,WES_3
BRCA1/2,1,"Sample Patient: A 4-year-old child is being evaluated for significant bilateral sensorineural hearing loss first recognized in infancy after failing the newborn hearing screen; they now use hearing aids with gradual progress but persistent speech delay. Family history is notable for a father with schizophrenia, and there is no known early-onset hearing or vision loss in other relatives. Prior chromosomal microarray testing was non-diagnostic. The child is insured through Cigna Open Access Plus. Their neonatologist has ordered germline BRCA1/2 testing to further evaluate the condition.",False,BRCA1/2_1
BRCA1/2,2,"Sample Patient: A 51-year-old woman with lifelong learning difficulties consistent with mild intellectual disability, first recognized in early childhood when she required special-education services, now presents at the request of her gynecologist to pursue BRCA1/2 germline testing; prior fluorescence in situ hybridization (FISH) testing was non-diagnostic, and family history is notable for a brother diagnosed with severe sensorineural hearing loss in early adolescence. She declined pre-test genetic counseling but was advised that post-test counseling can be arranged depending on results, and she is insured through UnitedHealthcare Choice Plus.",True,BRCA1/2_2
BRCA1/2,3,"Sample Patient: A 69-year-old adult with a history since early childhood of multiple congenital anomalies involving more than one organ system presents for further evaluation and test selection after a protracted course of surgeries and ongoing specialty follow-up; a prior karyotype was non-diagnostic and did not resolve the decision. Family history is notable for a brother who died suddenly and without explanation at age 32. The patient was referred by a medical geneticist and, after meeting with the genetics counselor on multiple occasions for pre-test counseling, is now pursuing BRCA1/2 testing with plans for post-test review. Coverage is through AARP Medicare Advantage from UnitedHealthcare (UHC).",True,BRCA1/2_3
CMA,1,"Sample Patient: Now 72 years old, the patient was referred by their oncologist for genetic evaluation given a history of a high-risk brief resolved unexplained event in early infancy that required cardiopulmonary resuscitation without a clear etiology, along with a maternal history of epithelial ovarian cancer; prior Fragile X testing was non-diagnostic. They have met with the genetic counselor on multiple occasions for pre-test education with plans for post-test follow-up, and are proceeding with chromosomal microarray analysis to assess for pathogenic copy-number variants. Insurance coverage for testing is through Cigna Medicare Advantage.",False,CMA_1
CMA,2,"Sample Patient: A 6-week-old infant was referred by their family medicine physician for evaluation of severe neurodevelopmental concerns, with poor feeding, limited visual tracking, and generalized hypotonia noted since birth, raising concern for evolving intellectual disability; the family history is notable for an older brother who had hypotonia in infancy. The family met with a genetic counselor prior to testing and plans to return for post-test counseling, and chromosomal microarray (CMA) is being pursued to investigate an underlying genetic etiology; the child is covered by Cigna.",True,CMA_2
CMA,3,"Sample Patient: A 6-year-old child with multiple congenital anomalies noted since infancy, without a unifying syndrome and accompanied by ongoing developmental concerns, was referred by the primary care pediatrician for further evaluation; the family history is notable for a maternal aunt with ovarian cancer. A prior chromosomal microarray was non-diagnostic, and given the persistent findings the pediatrician is now pursuing chromosomal microarray analysis targeted to developmental disorders. The child is insured through the Blue Cross Blue Shield Federal Employee Program (Service Benefit Plan).",True,CMA_3
CMA,4,"Sample Patient: A 0-year-old female neonate was referred by her pediatric oncologist for genomic evaluation in the context of a personal history of epithelial ovarian carcinoma, with concerns first arising prenatally when a third-trimester ultrasound suggested an adnexal mass; following delivery, she has remained clinically stable under oncologic management. Family history is notable for an older brother born with multiple congenital anomalies. A prior chromosomal microarray was non-diagnostic and did not clarify the etiology. At this time, chromosomal microarray analysis commonly used for developmental disorders is being pursued, despite the absence of pre-test genetic counseling to date. She is insured through the Blue Cross Blue Shield Service Benefit Plan (Federal Employee Program).",True,CMA_4
CMA,5,"Sample Patient: A 34-year-old adult with delays across multiple developmental domains, first recognized in early childhood, is being evaluated for ongoing difficulties with learning and adaptive skills; they were referred by their general practitioner to pursue chromosomal microarray analysis (CMA). Prior fluorescence in situ hybridization (FISH) testing was non-diagnostic and did not clarify the etiology. Family history is notable on the paternal side for a paternal aunt with breast cancer and a paternal grandfather with prostate cancer. The patient declined pre-test genetic counseling but received written information and will be re-offered post-test counseling once results are available. Insurance coverage is through Cigna under the Open Access Plus plan.",True,CMA_5
CMA,6,"Sample Patient: A 4-year-old child is being evaluated for decreased muscle tone, noted since infancy with poor head control in the first months of life, delayed sitting, and ongoing clumsiness without regression. The child was referred for genetic evaluation by the mother’s obstetrician, in the context of a family history notable for a maternal aunt with a known BRCA1 pathogenic variant, and a chromosomal microarray is being pursued to investigate the neuromotor and developmental concerns. The family has met with a genetic counselor on multiple occasions for pre-test counseling, with follow-up planned to review results and implications once available. Insurance coverage is through UnitedHealthcare Choice Plus.",False,CMA_6
CMA,7,"Sample Patient: A 71-year-old woman with lifelong developmental delays consistent with moderate intellectual disability, first evident in early childhood with delayed language and learning needs and formally diagnosed during adolescence, is referred by her gynecologist for genetic evaluation; chromosomal microarray analysis is being pursued to assess for a copy number variant etiology. She remains stable without regression but continues to require assistance with complex daily tasks. Family history is notable for her mother developing ovarian cancer in her 50s. Prior fluorescence in situ hybridization (FISH) testing was non-diagnostic and did not identify a cause. She is insured through the Blue Cross Blue Shield Federal Employee Program (Service Benefit Plan).",True,CMA_7
CMA,8,"Sample Patient: A 1-year-old child was referred by their family medicine physician for evaluation of global developmental delay concerning for intellectual disability, first recognized in early infancy as slower-than-expected attainment of developmental milestones. Family history is notable for an older brother with dysmorphic features. Prior Fragile X testing was non-diagnostic. Chromosomal microarray is being pursued at this time, with insurance coverage through UnitedHealthcare. The family declined pre-test genetic counseling; they were informed that post-test genetic counseling and follow-up discussion of results remain available if desired.",True,CMA_8
CMA,9,"Sample Patient: A 16-year-old with a history of intellectual disability presents for genetic evaluation after developmental delays were noted in early childhood, including late speech, learning difficulties requiring individualized education supports, and persistent adaptive challenges without apparent regression; they were referred by their cardiologist. Family history is notable for an older brother with severe intellectual disability diagnosed in childhood. Prior FISH testing was non-diagnostic. After pre-test counseling with a genetic specialist, a chromosomal microarray (CMA) is being pursued, with follow-up planned to review results and counseling implications. The patient is insured through UnitedHealthcare (UHC).",True,CMA_9
CMA,10,"Sample Patient: At 27 weeks’ gestation, a fetus was referred by the mother’s gynecologist for genetic evaluation because of concern for isolated neurodevelopmental delay without syndromic features, with concerns first raised earlier in the second trimester around 20 weeks’ gestation; family history is notable for a maternal uncle who reportedly has laboratory abnormalities suggestive of an inborn error of metabolism. Prenatal chromosomal microarray (CMA) is being pursued, and the parents have had multiple pre-test sessions with a genetic counselor with follow-up counseling planned once results are available. The family is insured through the Blue Cross Blue Shield Service Benefit Plan (FEP Blue).",False,CMA_10
WGS,1,"Sample Patient: At 28 weeks’ gestation, a fetus was referred by the obstetric nurse practitioner for genomic evaluation due to persistent concern—first noted around 20 weeks’ gestation—about risk for overall developmental delays that has continued through the pregnancy; the family reports an older brother with unexplained developmental regression in childhood that was not attributed to autism or epilepsy. Prior fluorescence in situ hybridization (FISH) testing was non-diagnostic. Prenatal whole-genome sequencing is being pursued to further clarify the etiology. The pregnancy is covered through UnitedHealthcare under the Choice Plus plan.",False,WGS_1
WGS,2,"Sample Patient: At 18 weeks’ gestation, this prenatal patient was referred by their primary care physician for evaluation of non-specific neurodevelopmental risk without a specific syndrome suspected, with concerns first arising in the early first trimester; a prior chromosomal microarray was non-diagnostic, and prenatal whole-genome sequencing is being pursued. Family history is notable for a maternal uncle with pancreatic cancer. The family declined pre-test genetic counseling, and post-test counseling will be offered pending results. Insurance coverage is through the Blue Cross Blue Shield Federal Employee Program (FEP Blue).",False,WGS_2
WGS,3,"Sample Patient: A 71-year-old woman with a history of two primary breast cancers—first diagnosed at age 47 and a contralateral new primary in her early 60s—presents for hereditary risk evaluation after prior surgeries and systemic therapy, and she remains under routine surveillance. She was referred by her medical geneticist for germline testing, and whole-genome sequencing is being pursued to clarify inherited cancer risk. She completed pre-test counseling with a genetic counselor and plans to return for post-test counseling once results are available. Family history is notable for a brother with a severe, longstanding immunologic disorder. Her coverage is through the Blue Cross and Blue Shield Service Benefit Plan (Federal Employee Program).",True,WGS_3
WGS,4,"Sample Patient: A 1-year-old infant with persistent low muscle tone noted in early infancy was referred by a pediatric neurologist to pursue whole-genome sequencing; a prior chromosomal microarray was non-diagnostic, and the family history is notable for a father with bipolar disorder. The child is insured through UnitedHealthcare (UHC), and no formal genetic counseling has yet been completed.",True,WGS_4
